Protocols

The available literature on BPC-157 (pentadecapeptide) dosing protocols is limited, as most reported studies have been conducted in animal models rather than human clinical trials. The following represents dosing information from available research:

Animal Studies

Animal research has used various dosing regimens, though specific protocols vary significantly across studies:

Studies examining cytoprotective effects in rats have used different administration routes including intraperitoneal, intragastric, and topical application
Dosing has ranged from microgram to milligram quantities per kilogram of body weight
Treatment durations have varied from acute single-dose studies to chronic administration over several weeks

Human Clinical Research

Currently, there is very limited published data on standardized human dosing protocols for BPC-157. One active clinical trial (NCT07437547) is investigating BPC-157 for acute hamstring muscle strain repair in a Phase 2 study, but dosing details and results are not yet available in the published literature.

Administration Routes

Research has explored multiple administration methods:

Injectable formulations (subcutaneous, intramuscular, intraperitoneal in animal studies)
Topical applications
Oral/intragastric delivery

Current Status

The biopharmaceutical literature notes significant challenges in formulation strategies and translational development barriers for BPC-157, indicating that standardized clinical protocols are still under investigation.

Important Disclaimer: The information above is for educational purposes only and represents research findings, not established clinical protocols. BPC-157 is an investigational compound without FDA approval for therapeutic use. This information is not personalized medical advice. Any consideration of BPC-157 use should involve consultation with qualified healthcare professionals familiar with current research and regulatory status.

Pentadecapeptide (BPC-157)

Member access required